Interim report January – March 2024 for CombiGene AB (publ)

January – March 2024
Net sales: TSEK 326 (2,168).
Other operating revenues: TSEK 1,042 (0).
Profit from financial items: TSEK -14,194 (-14,617).
Earnings per share: SEK -0.72 (-0.74).
Cash and cash equivalents: TSEK 90,318 (120,506).

Events during the period
• CombiGene regains the global rights to the epilepsy project CG01 as the termination period of the collaboration and
license agreement between the two companies has expired.
• CombiGene discontinues the preclinical development of the lipodystrophy project CGT2.
• CombiGene’s epilepsy project CG01 has been granted patent in two new countries, Australia and India.

Events after the end of the period
• CombiGene initiates collaboration with Västra Hamnen Corporate Finance.